Literature DB >> 14693591

Spinal 2-chloroprocaine: a dose-ranging study and the effect of added epinephrine.

Kristin N Smith1, Dan J Kopacz, Susan B McDonald.   

Abstract

UNLABELLED: With the availability of preservative- and antioxidant-free 2-chloroprocaine (2-CP), there may be an acceptable short-acting alternative to lidocaine for spinal anesthesia. We examined the safety, dose-response characteristics, and effects of epinephrine with spinal 2-CP. Six volunteers per group were randomized to receive 30, 45, or 60 mg of spinal 2-CP with and without epinephrine. Intensity and duration of sensory and motor blockade were assessed. When 11 of the 18 volunteers complained of vague, nonspecific flu-like symptoms, breaking of the blind revealed that all spinal anesthetics associated with the flu-like symptoms contained epinephrine. There were no complaints of flu-like symptoms in the volunteers who received 2-CP without epinephrine. No further spinal anesthetics containing epinephrine were administered, resulting in 29 anesthetics (11 with epinephrine, 18 without epinephrine.) Plain 2-CP demonstrated a dose-dependent increase in peak block height and duration of effect at all variables except time to 2-segment regression and time to regression to T10. Time to complete sensory regression with plain 2-CP was 98 +/- 20, 116 +/- 15, and 132 +/- 23 min, respectively. 2-CP with epinephrine produced times to complete sensory regression of 153 +/- 25, 162 +/- 33, and 148 +/- 29 min, respectively. Preservative and antioxidant free 2-CP can be used effectively for spinal anesthesia in doses of 30-60 mg. Epinephrine is not recommended as an adjunct because of the frequent incidence of side effects. IMPLICATIONS: Hyperbaric spinal 2-chloroprocaine is effective and has an anesthetic profile appropriate for use in the surgical outpatient over the dose range of 30-60 mg without signs of transient neurologic symptoms. The addition of epinephrine is not recommended because of the frequent incidence of side effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693591     DOI: 10.1213/01.ane.0000093361.48458.6e

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

Review 1.  Anaesthetic agents for advanced regional anaesthesia: a North American perspective.

Authors:  Chester C Buckenmaier; Lisa L Bleckner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Comparison of spinal anaesthesia with isobaric chloroprocaine and general anaesthesia for short duration ambulatory urological procedures.

Authors:  Siddarth Ravi; Handattu M Krishna
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2022-02-10

3.  Spinal Anesthesia Using Chloroprocaine is Safe, Effective, and Facilitates Earlier Discharge in Selected Fast-track Total Hip Arthroplasty.

Authors:  Carl L Herndon; Roxana Martinez; Nana O Sarpong; Jeffrey A Geller; Roshan P Shah; H John Cooper
Journal:  Arthroplast Today       Date:  2020-06-01

4.  A Prospective Open-Label Randomized Controlled Trial to Compare Intrathecal 1% 2-Chloroprocaine Versus 0.5% Bupivacaine in Ambulatory Elective Surgeries.

Authors:  Balwinderjit Singh; Asha Anand; Joginder Pal Attri
Journal:  Anesth Essays Res       Date:  2020-10-12

5.  Perioperative Outcomes in Patients Who Received Spinal Chloroprocaine for Total Hip or Knee Arthroplasty-Consecutive Case Series Study.

Authors:  Khaleifah Alhefeiti; Ana-Maria Patrascu; Sebastien Lustig; Frederic Aubrun; Mikhail Dziadzko
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

6.  Transient neurological symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics in adult surgical patients: a network meta-analysis.

Authors:  Patrice Forget; Josip A Borovac; Elizabeth M Thackeray; Nathan L Pace
Journal:  Cochrane Database Syst Rev       Date:  2019-12-01

7.  Spinal anaesthesia with Chloroprocaine HCl 1% for elective lower limb procedures of short duration: a prospective, randomised, observer-blind study in adult patients.

Authors:  Daniela Ghisi; Giorgia Boschetto; Alessandra Maria Spinelli; Sandra Giannone; Jacopo Frugiuele; Marcello Ciccarello; Stefano Bonarelli
Journal:  BMC Anesthesiol       Date:  2021-02-20       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.